Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugsAmedeo Capetti, Giuliano Rizzardini, Simona Landonio et al.|Medicine|2017Cited by 3
Benefit and costs of surveillance on cancer risk patients: the example of pancreatic cystic tumorsPaolo Angelo Cortesi, Gabriele Capurso, Domenico Tamburino et al.|European Journal of Public Health|2020Cited by 1